Henan Lingrui Pharmaceutical Beijing Drug Research Institute
Release time:
2021-12-23
Zhengzhou Lingrui Pharmaceutical Co., Ltd. is a high-tech pharmaceutical enterprise jointly invested by Henan Lingrui Pharmaceutical Co., Ltd., a publicly listed company with strong financial strength; Honghui Pharmaceutical Co., Ltd., which has strong market development capabilities; Beijing Gaobo Pharmaceutical Chemical Technology Co., Ltd., which has leading research and development levels in China; and Zhengzhou Dongfang Pharmaceutical Co., Ltd.
Zhengzhou Lingrui Pharmaceutical Co., Ltd. is a high-tech pharmaceutical enterprise jointly invested by Henan Lingrui Pharmaceutical Co., Ltd., a listed company with strong financial strength, Honghui Pharmaceutical Co., Ltd., which has strong market development capabilities, Beijing Gaobo Pharmaceutical Chemical Technology Co., Ltd., which has leading domestic R&D levels, and Zhengzhou Dongfang Pharmaceutical Co., Ltd.
The company covers an area of 146 acres, with a total construction area of nearly 30,000 square meters, built strictly according to GMP standards, with a fixed asset investment of 120 million yuan. The first phase of the project started construction in April 2002, mainly including the water injection workshop, office building, animal testing room, product analysis center, and water, electricity, and gas supply projects. In April 2003, the first phase of the project successfully passed the national GMP certification and officially went into production. The second phase of the project started in January 2004, simultaneously carrying out GMP transformation for tablets, capsules, oral liquids, and mixtures, as well as the expansion of the small water injection workshop and the construction of the synthesis workshop. In early September 2004, the tablet, capsule, oral liquid, and mixture workshops successfully passed GMP certification. In 2005, the small water injection workshop 2 and the synthesis workshop (raw material drug production workshop) will pass certification, and the relevant certification materials have been submitted to the Henan Provincial Medical Supervision Administration.
Zhengzhou Lingrui Pharmaceutical Co., Ltd. relies on the R&D advantages of Beijing Gaobo Pharmaceutical Chemical Technology Center and Beijing Honghui Pharmaceutical Biotechnology Research Institute, and is committed to building the company into a leading technology enterprise in China. The company currently has more than 100 pharmaceutical production batch numbers, with the cerebrovascular new drug—"Runtan" injection being a unique variety in the country, and the common injection products with a large market share in the country include: dexamethasone phosphate, glucose, ribavirin, anpain, and houttuynia cordata injection.
Once the company is fully completed, it will produce more than 1.5 billion injections annually, 1.2 billion capsules and tablets, and 8 tons of chemical raw materials (pharmaceutical intermediates). The annual sales revenue will exceed 600 million yuan, with profits and taxes of 120 million yuan, employing more than 1,000 staff. At that time, the company will become a major producer of small-volume injections and chemical raw materials in the country, and the most technologically advanced injection production enterprise in Henan Province.
Related Information
Beijing XinyiHuida Electromechanical
E-mail: xinyihuida@163.com
Mobile: +86-13911770565 Mr. Lin (General Manager)
Address: 415, 4th Floor, No.2 Jinguangnan Street, Jinguangnan Street, Xilu Street, Fangshan District, Beijing
Product Category
Copyright© Beijing XinyiHuida Electromechanical Equipment Co., Ltd